GlassScriptPhysician profile
Jamille Hernandez
NPI 1952758286
$492.33
in general payments reported to CMS, 2019-2025
13 companies · $81.54 in 2025
The $81.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $184 · 2021: $128 · 2023: $36.25 · 2024: $61.79 · 2025: $81.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149 · Long Term Medical Supply Or Device Loan: $30.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $149.37 |
| Long Term Medical Supply Or Device Loan | $30.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $114.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $84.96 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $52.56 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.23 | 2020-2021 | |
| Phadia US INC. | $35.34 | 2023-2024 | Immunocap |
| Baxter Healthcare | $30.21 | 2025 | Hillrom - Spot Vision Screener |
| Merck Sharp & Dohme LLC | $25.52 | 2020-2021 | |
| Esperion Therapeutics, INC. | $22.28 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.09 | 2021 | |
| Amgen INC. | $17.14 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.38 | 2021 | |
| Novo Nordisk INC | $14.38 | 2020 | |
| Eisai INC. | $13.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamille Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.